/term/net-income-including-noncontrolling-interests/TSE:4583 Chiome Bioscience (TSE:4583) Net Income Including Noncontro
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chiome Bioscience Inc (TSE:4583) » Definitions » Net Income Including Noncontrolling Interests

Chiome Bioscience (TSE:4583) Net Income Including Noncontrolling Interests : 円-1,296.4 Mil (TTM As of Mar. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Chiome Bioscience Net Income Including Noncontrolling Interests?

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Chiome Bioscience's Net Income Including Noncontrolling Interests for the three months ended in Mar. 2024 was 円-304.0 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Mar. 2024 was 円-1,296.4 Mil.


Chiome Bioscience Net Income Including Noncontrolling Interests Historical Data

The historical data trend for Chiome Bioscience's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chiome Bioscience Net Income Including Noncontrolling Interests Chart

Chiome Bioscience Annual Data
Trend Mar14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Income Including Noncontrolling Interests
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,403.82 -1,293.80 -1,479.90 -1,242.87 -1,220.02

Chiome Bioscience Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Income Including Noncontrolling Interests Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -227.68 -435.97 -254.81 -301.55 -304.02

Chiome Bioscience Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-1,296.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Chiome Bioscience Net Income Including Noncontrolling Interests Related Terms

Thank you for viewing the detailed overview of Chiome Bioscience's Net Income Including Noncontrolling Interests provided by GuruFocus.com. Please click on the following links to see related term pages.


Chiome Bioscience (TSE:4583) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chiome Bioscience Inc (TSE:4583) » Definitions » Net Income Including Noncontrolling Interests
Traded in Other Exchanges
N/A
Address
Sumitomo Fudosan Nishi-shinjuku Building No.6, 3-12-1, Honmachi, Shibuya-ku, Tokyo, JPN, 151-0071
Chiome Bioscience Inc is a Japanese based company engaged in the manufacture and sale of antibody drugs through the Autonomous Diversifying Library System. The business activity of the group is operated through Drug Discovery Alliance, Lead Antibody Licensing, and Licensing Out Platform Technology segments. The Drug Discovery Alliance segment partners with pharmaceutical companies to develop and create lead antibody drugs. The Lead Antibody Licensing Out segment is engaged in the production of specific antibodies against antigens and early licensing out to pharmaceutical manufacturers and the Licensing Out Platform Technology segment conducts research and development through the ADLib System. Geographically all the activities are functioned through Japan.

Chiome Bioscience (TSE:4583) Headlines

No Headlines